Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology

Puig, L.; Bordas, X.; Carrascosa, J.M.; Daudén, E.; Ferrándiz, C.; Hernanz, J.M.; López-Estebaranz, J.L.; Moreno, J.C.; Sánchez-Carazo, J.L.; Vanaclocha, F.; Vázquez-Veiga, H.

doi:10.1016/S1578-2190(09)70064-2

Información del artículo

Abstract

The treatment of psoriasis has been revolutionized by the introduction of biologic agents; these agents achieve skin clearance and long-term improvement without the risk of toxicity that has limited use of the traditional systemic treatments. The role of systemic treatment in the management of psoriasis is being reviewed on the basis of a large volume of scientific evidence on the efficacy and safety of biologic agents, and new therapeutic goals and strategies are being devised for patients with moderate to severe psoriasis. This has led to the need to establish severity criteria that will provide the rationale for the indication of the different systemic agents currently available for the treatment of moderate to severe psoriasis, as well as therapeutic goals, efficacy measures, therapeutic strategies, screening protocols, and choice of treatment based on the risk-benefit ratio of the different agents. These criteria must be established through consensus by experienced dermatologists and based on available scientific evidence. The present document reflects the consensus of the Spanish Psoriasis Group on these different issues in the management of moderate to severe psoriasis.

Key words:

psoriasis

treatment

consensus

criteria

biologic agents

Resumen

El tratamiento de la psoriasis se ha visto revolucionado por la introducción de los agentes biológicos, que permiten obtener blanqueamientos y mejorías a largo plazo sin el riesgo de toxicidad que ha venido limitando el tratamiento de estos pacientes con agentes sistémicos clásicos. Se ha acumulado abundante evidencia científica con respecto a la eficacia y seguridad de los agentes biológicos, que ha llevado a revisar el papel del tratamiento sistémico en general y ha permitido establecer nuevos objetivos y estrategias terapéuticas en los pacientes con psoriasis moderada a grave. En este contexto nuevo se hace necesario establecer, de forma consensuada por especialistas expertos y basada en la evidencia científica disponible, criterios de gravedad que justifiquen la indicación de los diferentes tratamientos sistémicos actualmente disponibles para la psoriasis, así como objetivos terapéuticos y parámetros de eficacia, estrategias de tratamiento, cribaje de los pacientes y selección del tratamiento basada en criterios de beneficio/riesgo. El presente documento recoge el consenso del Grupo Español de Psoriasis en estos diferentes aspectos del manejo de la psoriasis moderada a grave.

Palabras clave:

psoriasis

tratamiento

consenso

criterios

agentes biológicos

El Texto completo está disponible en PDF

References

[1.]

C. Ferrándiz, X. Bordas, V. García-Patos, S. Puig, R. Pujol, A. Smandía.

Prevalence of psoriasis in Spain (Epiderma Project: phase I).

J Eur Acad Dermatol Venereol, 15 (2001), pp. 20-23

Medline

[2.]

S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer Jr, D.M. Reboussin.

Psoriasis causes as much disability as other major medical diseases.

J Am Acad Dermatol, 41 (1999), pp. 401-407

Medline

[3.]

J.M. Gelfand, D.D. Gladman, P.J. Mease, N. Smith, D.J. Margolis, T. Nijsten, et al.

Epidemiology of psoriatic arthritis in the population of the United States.

J Am Acad Dermatol, 53 (2005), pp. 573

http://dx.doi.org/10.1016/j.jaad.2005.03.046 | Medline

[4.]

A. García-Díez, C. Ferrándiz-Foraster, F. Vanaclocha-Sebastián, L. Lizán-Tudela, X. Badia-Llach, G. Sellers-Fernández.

What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region.

Dermatology, 216 (2008), pp. 137-151

http://dx.doi.org/10.1159/000111511 | Medline

[5.]

A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman, For the National Psoriasis Foundation, et al.

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

J Am Acad Dermatol, 58 (2008), pp. 1031-1042

http://dx.doi.org/10.1016/j.jaad.2008.01.006 | Medline

[6.]

J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, X. Wang, et al.

The risk of mortality in patients with psoriasis: results from a population-based study.

Arch Dermatol, 143 (2007), pp. 1493-1499

http://dx.doi.org/10.1001/archderm.143.12.1493 | Medline

[7.]

R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, T. Rolstad.

Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.

J Investig Dermatol Symp Proc, 9 (2004), pp. 136-139

http://dx.doi.org/10.1046/j.1087-0024.2003.09102.x | Medline

[8.]

L. Puig-Sanz.

La psoriasis, ¿una enfermedad sistémica?.

Actas Dermosifiliogr, 98 (2007), pp. 396-402

Medline

[9.]

J.P. Callen, G.G. Krueger, M. Lebwohl, E.I. McBurney, P. Mease, A. Menter, et al.

AAD. AAD consensus statement on psoriasis therapies.

J Am Acad Dermatol, 49 (2003), pp. 897-899

http://dx.doi.org/10.1067/S0190 | Medline

[10.]

S.R. Feldman.

A quantitative definition of severe psoriasis for use in clinical trials.

J Dermatolog Treat, 15 (2004), pp. 27-29

http://dx.doi.org/10.1080/09541440042000269 | Medline

[11.]

J. Schmitt, G. Wozel.

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaquetype psoriasis.

Dermatology, 210 (2005), pp. 194-199

http://dx.doi.org/10.1159/000083509 | Medline

[12.]

A.Y. Finlay.

Current severe psoriasis and the Rule of Tens.

Br J Dermatol, 152 (2005), pp. 861-867

http://dx.doi.org/10.1111/j.1365-2133.2005.06502.x | Medline

[13.]

C. Ferrándiz Foraster, A. García-Díez, L. Lizán Tudela, L. Bermúdez-Rey, X. Badia Llach.

Impacto de la psoriasis en la calidad de vida relacionada con la salud.

Med Clin (Barc), 128 (2007), pp. 325-329

[14.]

D.M. Pariser, J. Bagel, J.M. Gelfand, N.J. Korman, C.T. Ritchlin, B.E. Strober, et al.

National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on disease severity.

Arch Dermatol, 143 (2007), pp. 239-242

http://dx.doi.org/10.1001/archderm.143.2.239 | Medline

[15.]

M. Augustin, K. Krüger, M.A. Radtke, I. Schwippl, K. Reich.

Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.

Dermatology, 216 (2008), pp. 366-372

http://dx.doi.org/10.1159/000119415 | Medline

[16.]

K. Reich, U. Mrowietz.

Treatment goals in psoriasis.

J Dtsch Dermatol Ges, 5 (2007), pp. 566-574

http://dx.doi.org/10.1111/j.1610-0387.2007.06343.x | Medline

[17.]

Y. Hongbo, C.L. Thomas, M.A. Harrison, M.S. Salek, A.Y. Finlay.

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?.

J Invest Dermatol, 125 (2005), pp. 659-664

http://dx.doi.org/10.1111/j.0022-202X.2005.23621.x | Medline

[18.]

A. Leon, A. Nguyen, J. Letsinger, J. Koo.

An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options.

Expert Opin Pharmacother, 8 (2007), pp. 617-632

http://dx.doi.org/10.1517/14656566.8.5.617 | Medline

[19.]

K.B. Gordon, S.R. Feldman, J.Y. Koo, A. Menter, T. Rolstad, G. Krueger.

Definitions of measures of effect duration for psoriasis treatments.

Arch Dermatol, 141 (2005), pp. 82-84

http://dx.doi.org/10.1001/archderm.141.1.82 | Medline

[20.]

A. Menter, C.E. Griffiths.

Current and future management of psoriasis.

Lancet, 370 (2007), pp. 272-284

http://dx.doi.org/10.1016/S0140-6736(07)61129-5 | Medline

[21.]

V. Rodríguez-Valverde, R. Cáliz Cáliz, J.M. Álvaro-Gracia Álvaro, J.M. Marenco de la Fuente, J. Mulero Mendoza, J. Tornero Molina, et al.

III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide.

Reumatol Clin, 2 (2006), pp. S52-S59

http://dx.doi.org/10.1016/S1699-258X(06)73097-2 | Medline

[22.]

P.I. Spuls, L. Witkamp, P.M. Bossuyt, J.D. Bos.

A systematic review of five systemic treatments for severe psoriasis.

Br JDermatol, 137 (1997), pp. 943-949

[23.]

V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, W.F. Goldschmidt, et al.

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.

N Engl J Med, 349 (2003), pp. 658-665

http://dx.doi.org/10.1056/NEJMoa021359 | Medline

[24.]

I. Flytström, B. Stenberg, A. Svensson, I.M. Bergbrant.

Methotrexate vs. cyclosporine in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.

Br J Dermatol, 158 (2008), pp. 116-121

http://dx.doi.org/10.1111/j.1365-2133.2007.08284.x | Medline

[25.]

R. Gamo, J.L. López-Estebaranz.

Terapia biológica y psoriasis.

Actas Dermosifiliogr, 97 (2006), pp. 1-17

Medline

[26.]

A. Nast, I.B. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, M. Follmann, et al.

Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

J Dtsch Dermatol Ges, 5 (2007), pp. 1-119

http://dx.doi.org/10.1111/j.1610-0387.2007.06172.x | Medline

[27.]

R.G. Langley, V. Ho, C. Lynde, K.A. Papp, Y. Poulin, N. Shear, et al.

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.

J Cutan Med Surg, 9 (2006), pp. 18-25

http://dx.doi.org/10.1007/s10227-006-0103-1 | Medline

[28.]

R.G. Langley, K.B. Gordon.

Duration of remission of biologic agents for chronic plaque psoriasis.

J Drugs Dermatol, 6 (2007), pp. 1205-1212

Medline

[29.]

A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, A. Menter.

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.

Br J Dermatol, 159 (2008), pp. 274-285

http://dx.doi.org/10.1111/j.1365-2133.2008.08673.x | Medline

[30.]

J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, J.P. Ortonne, CHAMPION Study Investigators, et al.

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

Br J Dermatol, 158 (2008), pp. 558-566

http://dx.doi.org/10.1111/j.1365-2133.2007.08315.x | Medline

[31.]

A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, R.G. Langley, et al.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

J Am Acad Dermatol, 58 (2008), pp. 106-115

http://dx.doi.org/10.1016/j.jaad.2007.09.010 | Medline

[32.]

K. Gordon, S. Tyring, Y. Gu, M. Okun.

P2654. Psoriasis patients treated continuously with adalimumab: efficacy and safety results from months 12 to 18.

J Am Acad Dermatol, 58 (2008), pp. AB129

[33.]

P.C. Van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, A. Kaszuba, et al.

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderateto- severe plaque psoriasis: a randomized controlled trial with open-label extension.

Br J Dermatol, 159 (2008), pp. 1177-1185

http://dx.doi.org/10.1111/j.1365-2133.2008.08771.x | Medline

[34.]

M. Lebwohl, J. Bagel, J.M. Gelfand, D. Gladman, K.B. Gordon, S. Hsu, et al.

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

J Am Acad Dermatol, 58 (2008), pp. 94-105

http://dx.doi.org/10.1016/j.jaad.2007.08.030 | Medline

☆

The Spanish Psoriasis Group is a working group of the Spanish Academy of Dermatology and Venereology. The 50 members of the group are dermatologists working in hospital settings who have special expertise in the treatment of patients with psoriasis and are involved in clinical and therapeutic research in this specialized area.

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter